KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies.

Sonja Ständer, Sarina B Elmariah, Shawn G Kwatra, Gil Yosipovitch, Andrew E Pink, Soo Yeon Cheong, Xiaoxiao Chen, Zarif K Jabbar-Lopez, Liliana Ulianov, Christophe Piketty, Jonathan I Silverberg

J Eur Acad Dermatol Venereol 40(5) 867-875

PMID41401055
PMCIDPMC13109751
DOI10.1111/jdv.70250
发表日期2025-12-16
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:FIGURE 1:图注未提示 KM 曲线;FIGURE 2:图注未提示 KM 曲线;FIGURE 3:图注未提示 KM 曲线;FIGURE 4:非 KM 图。
摘要

摘要

BACKGROUND/OBJECTIVES: Itch is the most burdensome symptom in atopic dermatitis (AD) and prurigo nodularis (PN) and is associated with significant psychological distress, sleep deprivation and impaired quality of life. Achieving rapid control of itch is expected to minimize symptomatology and disease burden. Nemolizumab, which targets the interleukin 31 (IL-31) pathway, rapidly relieved itch in Phase 2 trials; thus, a post hoc analysis of four pivotal randomized controlled clinical trials of nemolizumab in AD and PN was performed to further evaluate the improvement of itch over the first 14 days of therapy. METHODS: Data from ARCADIA 1 and 2 in AD (N = 1728) and OLYMPIA 1 and 2 in PN (N = 560) were analysed. Patients reported itch intensity and sleep disturbance daily. Differences in the proportion of itch and sleep responders (patients with ≥4-point improvement from baseline in peak pruritus numerical rating scale [PP-NRS] or sleep disturbance [SD-NRS] score) between nemolizumab and placebo groups were calculated. RESULTS: Nemolizumab rapidly reduced itch in AD (ARCADIA 1 and 2), with a difference versus placebo in PP-NRS responders apparent by Day 2 (pooled data: 10.7% vs. 2.9%; 95% CI: 5.6-10.1; p < 0.0001) that steadily increased through Day 14. Nemolizumab also reduced itch rapidly in PN (OLYMPIA 1 and 2); a difference versus placebo occurred by Day 2 (pooled data: 17.2% vs. 3.7%; 95% CI: 6.8-16.7; p < 0.0001). Early improvement (Day 2) was also observed in sleep in nemolizumab-treated patients. In pooled analyses in AD, 9.9% (nemolizumab) versus 4.6% (placebo; 95% CI: 2.8-7.7; p = 0.0001) were SD-NRS responders and in PN, 13.4% versus 4.3% (95% CI: 4.0-13.0; p = 0.0013). Itch and sleep response data in individual studies were consistent with the pooled data. CONCLUSIONS: This analysis confirms previously reported data that nemolizumab relieves itch and sleep disturbance by Day 2 in patients with moderate-to-severe AD and PN, indicating that targeting the IL-31 pathway presents an important way to achieve rapid itch response.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1Pooled analysis of daily proportion of patients with improvement in PP‐NRS ≥4 points in ARCADIA 1 and 2 (a) and OLYMPIA 1 and 2 (b). Nemolizumab indicated by blue lines, placebo indicated by grey lines. BL, baseline; ITT, intent‐to‐treat; N , total number of patients; NRI, non‐responder imputation; PP‐NRS, peak pruritus numerical rating scale; TCI, topical calcineurin inhibitors; TCS, topical corticosteroids. Percentage (%) are based on the number of patients in each treatment group ( N ).
非 KM Figure
FIGURE 2Individual trial data from ARCADIA 1 and 2 (a) and OLYMPIA 1 and 2 (b) of PP‐NRS responders show the consistency of results between studies. BL, baseline; ITT, intent‐to‐treat; N , total number of patients; NRI, non‐responder imputation; PP‐NRS, peak pruritus numerical rating scale; TCI, topical calcineurin inhibitors; TCS, topical corticosteroids. Percentage (%) are based on the number of patients in each treatment group ( N ).
非 KM Figure
FIGURE 3Pooled sleep responder data for ARCADIA 1 and 2 (a) and OLYMPIA 1 and 2 (b). BL, baseline; ITT, intent‐to‐treat; N , total number of patients; NRI, non‐responder imputation; SD‐NRS, sleep disturbance numerical rating scale; TCI, topical calcineurin inhibitors; TCS, topical corticosteroids. Percentage (%) are based on the number of patients in each treatment group ( N ).
非 KM Figure
FIGURE 4Individual trial data from ARCADIA 1 and 2 (a) and OLYMPIA 1 and 2 (b) of SD‐NRS responders show the consistency of results between studies. BL, baseline; ITT, intent‐to‐treat; N , total number of patients; NRI, non‐responder imputation; SD‐NRS, sleep disturbance numerical rating scale; TCI, topical calcineurin inhibitors; TCS, topical corticosteroids. Percentage (%) are based on the number of patients in each treatment group ( N ).
非 KM Figure